Understanding Ductal Carcinoma In Situ (DCIS): Causes, Diagnosis, and Treatment Options

Ductal carcinoma in situ (DCIS) is a non‑invasive breast lesion in which abnormal cells line a milk duct but have not spread beyond it. Because the disease remains confined to the ductal system, it has an excellent cure rate.

DCIS is classified as stage 0 or pre‑invasive cancer, meaning it is a precursor to invasive breast cancer if left untreated.

The breast is composed of three main tissue types:

• Lobules: tiny sacs that produce milk.
• Ducts: channels that transport milk to the nipple.
• Connective tissue: fatty or fibrous tissue that surrounds the lobules and ducts.

DCIS develops when a cluster of abnormal cells begins to grow inside the lining of a duct. Since these cells have not breached the duct wall, the cancer is considered non‑invasive.

If untreated, some DCIS lesions can progress to invasive breast cancer, which can spread (metastasize) to other parts of the body.

In the United States, an estimated 20–25 % of newly diagnosed breast cancers are DCIS.

Most people with DCIS have no noticeable symptoms. The abnormal cells are usually discovered incidentally on a screening mammogram as clusters of bright white specks called microcalcifications, often with irregular shapes.

Occasionally, DCIS may cause nipple discharge that is not milk or a small palpable lump, but the majority of breast changes are benign.

While the exact cause of DCIS remains unknown, several factors can increase a woman’s risk of developing breast cancer, including age, family history, genetic mutations, and certain lifestyle choices. Having one or more risk factors does not guarantee a diagnosis, but awareness helps guide screening and prevention strategies.

Diagnosis typically follows a routine mammogram. If a radiologist suspects DCIS, additional imaging and a core‑needle or surgical biopsy are performed to confirm the presence of abnormal cells and to assess hormone‑receptor status (estrogen and/or progesterone receptors).

Pathology reports often contain technical terms; for example, hormone‑receptor positivity may influence the decision to prescribe anti‑estrogen medication to lower recurrence risk.

Because DCIS is detected at an early stage, treatment is highly effective, and chemotherapy is never indicated.

Below are the most common treatment approaches, selected based on the size, location, and biology of the lesion.

Lumpectomy

Also called breast‑conserving surgery, a lumpectomy removes the duct containing DCIS together with a margin of surrounding healthy tissue.

Mastectomy

A mastectomy removes all breast tissue. It is recommended when DCIS is multifocal (present in several areas) or when the affected area is large.

Radiation therapy

Radiation is usually given after a lumpectomy to reduce the chance of recurrence. High‑energy beams target the surgical cavity, damaging the DNA of any remaining abnormal cells while sparing surrounding tissue.

Hormone therapy

If the tumor is hormone‑receptor‑positive, anti‑estrogen drugs can be added after surgery. Tamoxifen blocks estrogen receptors, while aromatase inhibitors lower estrogen production in post‑menopausal women.

According to the National Breast Cancer Research Foundation, the 10‑year survival rate for DCIS is 98 %. Moreover, 50–80 % of DCIS cases never progress to invasive disease.

Important considerations

Women diagnosed with DCIS before age 40 and Black women experience a higher risk of breast‑cancer‑related mortality—approximately 40 % higher for Black women compared with White women. Social determinants of health, including chronic stress from racism and discrimination, may contribute beyond genetic factors.

Long‑term follow‑up with regular mammograms and clinical exams is essential to monitor for recurrence.

In summary, DCIS is a pre‑invasive breast cancer with a very high cure rate. It is most often asymptomatic and discovered on screening mammography. Treatment—ranging from lumpectomy to mastectomy, often combined with radiation and/or hormone therapy—offers excellent outcomes, with a 98 % ten‑year survival rate.